Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study.
Atsuko TsujiiKentaro IsodaMaiko YoshimuraAkihiko NakabayashiDong-Seop KimTatsuya TamadaKurumi YamamotoShiro OhshimaPublished in: BMC rheumatology (2024)
JAKi is as safe and effective as ABT for patients with RA-ILD. JAKi can be a good treatment option for such patients.